ES2376930B1 - METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES. - Google Patents

METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES. Download PDF

Info

Publication number
ES2376930B1
ES2376930B1 ES200900331A ES200900331A ES2376930B1 ES 2376930 B1 ES2376930 B1 ES 2376930B1 ES 200900331 A ES200900331 A ES 200900331A ES 200900331 A ES200900331 A ES 200900331A ES 2376930 B1 ES2376930 B1 ES 2376930B1
Authority
ES
Spain
Prior art keywords
treatment
neurodegenerative diseases
hyperphosphorylated tau
tau protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200900331A
Other languages
Spanish (es)
Other versions
ES2376930A1 (en
Inventor
Gorka Orive Arroyo
Rosa María Hernández Martín
Carlos Spuch Calvar
Desiree Antequera Tienda
Félix Bermejo-Pareja
Eva Carro Díaz
José Luis Pedraz Muñoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euskal Herriko Unibertsitatea
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas CIBERNED
Fundacion Investigacion Biomedica Hospital Universitario 12 Octubre
Original Assignee
Euskal Herriko Unibertsitatea
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas CIBERNED
Fundacion Investigacion Biomedica Hospital Universitario 12 Octubre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euskal Herriko Unibertsitatea, Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas CIBERNED, Fundacion Investigacion Biomedica Hospital Universitario 12 Octubre filed Critical Euskal Herriko Unibertsitatea
Priority to ES200900331A priority Critical patent/ES2376930B1/en
Priority to PCT/ES2010/070059 priority patent/WO2010089442A1/en
Publication of ES2376930A1 publication Critical patent/ES2376930A1/en
Application granted granted Critical
Publication of ES2376930B1 publication Critical patent/ES2376930B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Método para el tratamiento de enfermedades neurodegenerativas. La presente invención se relaciona, en general, con una composición o kit que comprende un factor angiogénico para el tratamiento de enfermedades neurodegenerativas, para revertir el efecto tóxico producido por la proteína beta amiloide (1-42) o la proteína tau hiperfosforilada, para disminuir la cantidad de proteína tau hiperfosforilada y/o para prevenir la formación de ovillos neurofibrilares.Method for the treatment of neurodegenerative diseases. The present invention relates, in general, to a composition or kit comprising an angiogenic factor for the treatment of neurodegenerative diseases, to reverse the toxic effect produced by beta amyloid protein (1-42) or hyperphosphorylated tau protein, to decrease the amount of hyperphosphorylated tau protein and / or to prevent the formation of neurofibrillar clews.

ES200900331A 2009-02-05 2009-02-05 METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES. Expired - Fee Related ES2376930B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200900331A ES2376930B1 (en) 2009-02-05 2009-02-05 METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
PCT/ES2010/070059 WO2010089442A1 (en) 2009-02-05 2010-02-04 Method for treating neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900331A ES2376930B1 (en) 2009-02-05 2009-02-05 METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Publications (2)

Publication Number Publication Date
ES2376930A1 ES2376930A1 (en) 2012-03-21
ES2376930B1 true ES2376930B1 (en) 2013-01-24

Family

ID=42541698

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200900331A Expired - Fee Related ES2376930B1 (en) 2009-02-05 2009-02-05 METHOD FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Country Status (2)

Country Link
ES (1) ES2376930B1 (en)
WO (1) WO2010089442A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213768A1 (en) * 1999-04-30 2004-10-28 Elliott Robert Bartlett Preparation for biotransplantation and xenotransplantion and uses thereof
EP1272208B1 (en) * 2000-04-12 2011-10-05 VIB vzw Use of vegf 165 and homologues to treat neuron disorders
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
JP2007506754A (en) * 2003-09-23 2007-03-22 ラドウィグ インスティテュート フォー キャンサー リサーチ VEGF-C or VEGF-D substances and methods for stimulation of neural stem cells
ES2332169B1 (en) * 2008-07-24 2010-10-25 Universidad Del Pais Vasco EMPLOYMENT OF MICROPARTICLES THAT INCLUDE GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Also Published As

Publication number Publication date
WO2010089442A1 (en) 2010-08-12
ES2376930A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
CY2016029I2 (en) SUBTILYSIN KEKIN-TYPE 9 (PCSK9) ANTIGEN-BINDING PROTEIN-CONVERTING PROTEIN
DK2134201T3 (en) Multicomponent filter which provides enhanced flavor enhancement
DK2480574T3 (en) ANTI-CD33 ANTIBODIES AND THEIR USE FOR IMMUNOTARGETING IN THE TREATMENT OF CD33-ASSOCIATED DISEASES
BRPI0814687A2 (en) IN VITRO METHOD TO INHIBIT A MEMBER OF THE RHO GTPASE FAMILY, COMPOUND, AND PHARMACEUTICAL COMPOSITION.
BRPI0905369A2 (en) Pharmaceutical composition, composition and compartmentalized kit
DK2136117T3 (en) Balanced solenoid valve
BRPI0813306A2 (en) compound, pharmaceutical composition, method for producing inhibition of a cysteine protease in a mammal, and use of a compound.
DK2177536T3 (en) Antibodies to amyloid beta peptide
BRPI1013891A2 (en) zinc finger protein transcription factor dst and its use to regulate drought tolerance and salinity.
CO6670526A2 (en) Beta amyloid anti-n3p glu peptide antibodies and uses thereof
DK2099826T3 (en) ANTI-BETA AMYLOID ANTIBODY AND APPLICATIONS THEREOF
DK2004204T3 (en) Treatment of selenate neurodegenerative diseases
EA201101117A1 (en) DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES IN CHILDREN
NO20090904L (en) Multicomponent filter which provides multiple flavor enhancement
BRPI1010307A2 (en) compositions and methods related to a (spa) protein variants.
BRPI0906549A2 (en) Medical bandages with valves and kits containing them.
DK2114386T3 (en) Pharmaceutical composition for the treatment of diabetes complications
DK2033641T3 (en) Process for the preparation of extracts rich in proanthocyanidins
CR10556A (en) HUMANIZED ANTIBODY AGAINST AMYLOID BETA
FR2918570B1 (en) DIGLYCATION OF AGEs.
BRPI0923544A2 (en) anti-idiotype antibody against an antibody against amyloid beta peptide
BRPI0916936A2 (en) pharmaceutical compositions and methods for producing low impurity concentrations thereof.
BRPI0915078A2 (en) solenoid valve
BRPI0918204A2 (en) igv variant pharmaceutical composition and kit
DK2172207T3 (en) Pharmaceutical composition for the treatment of diabetes and its method of preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2376930

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130124

FD2A Announcement of lapse in spain

Effective date: 20210915